AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11990278
Drug: Remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 microg kg(‐1) over 30 s, followed by an infusion of 0.1 microg kg min(‐1) (group R)
Trial: 11990278
Drug: Alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 10 microg kg(‐1) over 30 s, followed by an infusion of saline (group A)
Trial: 10710173
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (0.325 mg/kg)
Trial: 10710173
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (0.650 mg/kg)
Trial: 10710173
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (0.325 mg/kg) and (0.650 mg/kg)
Trial: 7815715
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin 50 mg plus epidural 0.1 mg buprenorphine in 8 ml of 0.25% bupivacaine and 15 micrograms buprenorphine in 1 ml of 0.25% bupivacaine at 1 ml.h‐1 for 48 h
Trial: 7815715
Drug: Epidural 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 0.1 mg buprenorphine in 8 ml of 0.25% bupivacaine and 15 micrograms buprenorphine in 1 ml of 0.25% bupivacaine at 1 ml.h‐1 for 48 h
Trial: 22164930
Drug: Guided group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided group medical art therapy (MAT) for 6 weeks, facilitated by a MAT therapist.
Trial: 19809344
Drug: EP-2104R (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-2104R (4 mumol/kg intravenous bolus injection)
Trial: 16969009
Drug: Single 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 0.5 mg ACTH-depot doses for the entire duration of pregnancy
Trial: 16969009
Drug: Series of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Series of three 0.5 mg ACTH-depot injections every other day in the first and/or second trimester
Trial: 9250558
Drug: Bromfenac 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 50 mg (3 times/day for 3 days)
Trial: 8220804
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg once daily for two weeks
Trial: 3470961
Drug: PGE1 treatment
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 treatment group (0.2 ng/kg body weight/min and 15,000 I.U. heparin/d for 10 days)
Trial: 3470961
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3 x 500 mg aspirin and 15,000 I.U. heparin/d)
Trial: 30273586
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of extended‐release liposomal bupivacaine (Exparel)
Trial: 30273586
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of placebo (saline)
Trial: 22967782
Drug: Naltrexone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone maintenance dose
Trial: 15907239
Drug: Oral Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Misoprostol (50 microg, 4 hourly to a maximum of four doses)
Trial: 15907239
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal pessary (at 6 hourly intervals up to two doses)
Trial: 12769340
Drug: iCNOP (mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCNOP (mitoxantrone 20 mg/m2, i.v., d.1)
Trial: 7485077
Drug: Loperamide 4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 4 mg po q6h
Trial: 7485077
Drug: Octreotide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide at higher dosage levels (dose escalated to maximum of 2,400 micrograms)
Trial: 19432126
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of active vitamin D3 and alendronate
Trial: 19432126
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of risedronate and vitamin K2
Trial: 15488108
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (CBT)
Trial: 15488108
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy (CBT)
Trial: 11159242
Drug: Levobupivacaine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine and fentanyl 2 microg/mL
Trial: 11159242
Drug: Levobupivacaine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine and fentanyl 3 microg/mL
Trial: 9779700
Drug: Dexamethasone, high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, high‐dose cytarabine, and cisplatin (DHAP)
Trial: 3207529
Drug: 4% amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% amethocaine formulation
Trial: 3207529
Drug: Higher concentrations
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher concentrations of amethocaine (12%) in formulation C
Trial: 3207529
Drug: Formulations A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations A and B (hydrophilic)
Trial: 3207529
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C (oil-in-water cream)
Trial: 2119530
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg/day during 1 week)
Trial: 2119530
Drug: Adrenaline infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusions (0.1 and 0.4 nmol kg‐1 min‐1)
Trial: 786348
Drug: Adrenaline 5
RxNorm normalized name: Adrenaline 5 mg/mL eye solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 5 mug/ml added to 1% etidocaine hydrochloride
Trial: 31956998
Drug: Intensified regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified regimen with rifampin 15 mg/kg and levofloxacin for the first 60 days
Trial: 31956998
Drug: Rifampin 15
RxNorm normalized name: rifampin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 15 mg/kg
Trial: 31754048
Drug: Propranolol (80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80-160 mg daily for 7 days)
Trial: 28385346
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Trial: 28385346
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Trial: 17286624
Drug: Oxcarbazepine (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (initiated at 300 mg/day, titrated to a maximum of 900 mg b.i.d.)
Trial: 11309009
Drug: ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 7.5 mg. ml‐1
Trial: 11309009
Drug: ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 7.5 mg. ml‐1 + 1 microg. ml‐1 fentanyl
Trial: 3297574
Drug: 4-aminosalicylic acid
RxNorm normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-aminosalicylic acid (4-ASA) enemas, 1 g bid
Trial: 3297574
Drug: 4-aminosalicylic acid
RxNorm normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-aminosalicylic acid (4-ASA) enemas, 2 g bid
Trial: 31411975
Drug: PSA >40ng/ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA >40ng/ml, GGG5, and GGG4
Trial: 29550184
Drug: Pre-treatment computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment computed tomography (CT) findings
Trial: 28089187
Drug: Multimodal cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cocktail injection with morphine (10 mg)
Trial: 28089187
Drug: Multimodal cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cocktail injection without morphine
Trial: 26018036
Drug: Nasal mupirocin
RxNorm normalized name: mupirocin Nasal Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal mupirocin (Bactroban) twice daily and hexachlorophene (pHIsoHex) soaps daily for 7 days
Trial: 23812521
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection (PRPplus group)
Trial: 9890611
Drug: Preterm newborns
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm newborns (mean 4.6+/‐6.9 ng/mL)
Trial: 9890611
Drug: Term newborns
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Term newborns (mean 19.6+/‐14.3 ng/mL)
Trial: 9890611
Drug: Newborns at
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newborns at approximately 6 days of life (mean 1.9+/‐1.1 ng/mL)
Trial: 8915402
Drug: Taurine powder
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine powder (6 g/day)
Trial: 1853148
Drug: Cimetidine, 400
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 400 mg twice a day
Trial: 1905501
Drug: Sucralfate, 1
RxNorm normalized name: Sucralfate, 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, 1 g four times a day
Trial: 6421002
Drug: Gallopamil (D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (D 600) 50 mg
Trial: 6421002
Drug: Gallopamil (D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (D 600) 150 mg
Trial: 27352907
Drug: Patch tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch tests including baseline series plus selected allergens
Trial: 20537406
Drug: Motivation enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivation enhancement therapy (MET)
Trial: 18467543
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + Caff (8 mg/kg BM)
Trial: 18467543
Drug: CHO (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (4 g/kg body mass)
Trial: 15305841
Drug: Intracerebral microdialysis
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracerebral microdialysis and bedside biochemical analyses for monitoring cerebral energy metabolism.
Trial: 7598280
Drug: Milrinone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (loading dose of 50-75 micrograms/kg followed by 0.5-0.75 micrograms.kg-1.min-1 for 12-24 h)
Trial: 368975
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamin B6 (pyridoxine)
Trial: 31065844
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake ≥ 1.1 g/kg BW
Trial: 31065844
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake < 1.1 g/kg BW
Trial: 30933748
Drug: Individually delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually delivered treatment
Trial: 30933748
Drug: Trauma-focused treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused treatments
Trial: 29237915
Drug: Auricular points
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auricular points treatment combined with acupoints application therapy
Trial: 22871333
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 800 mg once-daily, individualized within 400-1200 mg range
Trial: 19701676
Drug: Rasburicase 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasburicase 0.15 mg/kg/day
Trial: 11201510
Drug: Isoflavone-rich soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-rich soy protein (80.4 mg/day)
Trial: 11201510
Drug: Isoflavone-poor soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-poor soy protein (4.4 mg/day)
Trial: 396111
Drug: Alprenolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (200 mg twice daily for 8 weeks)
Trial: 25591723
Drug: Antiarrhythmic medication
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic medication (group II, 46 pts)
Trial: 19925617
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg and 1.8 mg once-daily) plus OADs
Trial: 19925617
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg and 1.8 mg once-daily) plus metformin or metformin plus rosiglitazone
Trial: 19925617
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg and 1.8 mg once-daily) plus glimepiride
Trial: 19085384
Drug: Copaxone (glatiramer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copaxone (glatiramer acetate) 20 mg weekly subcutaneous injections for 12 weeks
Trial: 16816306
Drug: Nurse problem-solving
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse problem-solving treatment
Trial: 14710057
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution placebo with epinephrine
Trial: 2035325
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg peroral vitamin K
Trial: 2035325
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intramuscular vitamin K
Trial: 7016626
Drug: Trimethoprim 200
RxNorm normalized name: trimethoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 200 mg x 2 for 10 days
Trial: 7016626
Drug: Nitrofurantoin 50
RxNorm normalized name: nitrofurantoin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 50 mg x 4 for 10 days
Trial: 28701602
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 mcg/kg) over 10 min before propofol (1 mg/kg)
Trial: 28701602
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg) only
Trial: 24876244
Drug: Intravenous tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue-type plasminogen activator
Trial: 19725966
Drug: Artesunate-mefloquine combination
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine combination therapy
Trial: 15093200
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and radiation therapy
Trial: 15093200
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with chemotherapy first followed by radiation
Trial: 2901270
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg kg‐1
Trial: 29474602
Drug: Haemodialysis patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemodialysis patients with BTP concentration >7.96 mg/L
Trial: 29474602
Drug: Coronary angiography
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary angiography patients with BTP concentration >0.67 mg/L
Trial: 25563312
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (GCV) 1000 mg 3 times per day for 8 weeks, plus topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Trial: 25563312
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir (ACV) with the same ophthalmic gel and eye drops, plus oral ACV 400 mg 5 times a day for 10 weeks, then 400 mg 2 times per day for 6 months.
Trial: 25563312
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control (placebo) group with topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Trial: 17142146
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg daily with placebo colesevelam HCl twice daily (E)
Trial: 17142146
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg daily with 1.875 g colesevelam HCl twice daily (E + C)
Trial: 10873879
Drug: 8-L exchanges
RxNorm normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-L exchanges
Trial: 10873879
Drug: 6-L exchanges
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-L exchanges
Trial: 10873879
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3 daily 2-L exchanges)
Trial: 9110103
Drug: identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo capsules
Trial: 8249364
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (rhEpo) 6 x 10,000 U administered 4 and 2 weeks before surgery
Trial: 8249364
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (rhEpo)
Trial: 3900456
Drug: TMS-19-Q.GC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMS-19-Q.GC tablet (TMS) at a dosage of 600 mg daily
Trial: 3900456
Drug: Midecamycin (MDM)
RxNorm normalized name: midecamycin
DrugBank: Midecamycin (DB13456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midecamycin (MDM) at a dosage of 1200 mg daily
Trial: 31846475
Drug: COR-1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COR-1 (1 mg DNA administered intradermally as two injections of 500 μg each)
Trial: 31846475
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered intradermally as two injections of 500 μg each)
Trial: 29431027
Drug: Standard-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care treatment administered by their oncologist
Trial: 24189254
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg single-dose primaquine (PMQ)
Trial: 24189254
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg daily for 14 days
Trial: 24189254
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg twice daily
Trial: 24189254
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg 7-day PMQ regimen
Trial: 22922489
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (IM) therapy in early chronic phase (ECP)
Trial: 22922489
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (IM) therapy in late chronic phase (LCP)
Trial: 20799042
Drug: Usual endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual endurance training supplemented with heavy strength training twice a week during a 12-week preparatory period followed by strength maintenance training once a week during the first 13 weeks of a competition period (E + S)
Trial: 18003562
Drug: Insomnia medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insomnia medication (verum)
Trial: 9467549
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2; 0.1 mg every 3.5 days; n = 48)
Trial: 9467549
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (1.25 mg every day; n = 49)
Trial: 9467549
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) and Oral conjugated equine estrogens
Trial: 21679511
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intravenous methylprednisolone
Trial: 21679511
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg intravenous methylprednisolone